Disparities in Receipt of Smoking Cessation Assistance Within the US

Maki, Kristin G.; Volk, Robert J.

doi:10.1001/jamanetworkopen.2022.15681

Cited by 11 publications

(14 citation statements)

References 5 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…states), 3 indicating a similar LCS prevalence rate in 2021 and 2022 (19.6%). A limitation of our study was that BRFSS LCS data are self-reported.…”

Section: Discussionmentioning

confidence: 75%

“…2 Despite recommendations, LCS uptake has been low, with 2021 data from 4 states reporting 21% of eligible individuals screened. 3 National estimates of LCS prevalence are limited. Hence, we sought to compare LCS prevalence in 2022 by sociodemographic characteristics and by state among individuals eligible per 2013 vs 2021 USPSTF recommendations.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Lung Cancer Screening in the US, 2022

Henderson,

Su,

Rivera

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

“…states), 3 indicating a similar LCS prevalence rate in 2021 and 2022 (19.6%). A limitation of our study was that BRFSS LCS data are self-reported.…”

Section: Discussionmentioning

confidence: 75%

Section: Introductionmentioning

confidence: 99%

Prevalence of Lung Cancer Screening in the US, 2022

Henderson,

Su,

Rivera

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

“…The ACR Lung Cancer Screening Registry estimated that the national rate of LCS was only 5% in 2018, although it varied significantly by state 39 . The most recent LCS rates come from four US states that included LCS questions in the Behavioral Risk Factor Surveillance System in 2021 126 . Individuals eligible for LCS reported recent screening ranging from 17.5% in New Jersey to 30.3% in Rhode Island 126 …”

Section: Discussionmentioning

confidence: 99%

“…The most recent LCS rates come from four US states that included LCS questions in the Behavioral Risk Factor Surveillance System in 2021 126 . Individuals eligible for LCS reported recent screening ranging from 17.5% in New Jersey to 30.3% in Rhode Island 126 …”

Section: Discussionmentioning

confidence: 99%

Screening for lung cancer: 2023 guideline update from the American Cancer Society

Wolf,

Oeffinger,

Shih

et al. 2023

CA A Cancer J Clinicians

View full text Add to dashboard Cite

Lung cancer is the leading cause of mortality and person‐years of life lost from cancer among US men and women. Early detection has been shown to be associated with reduced lung cancer mortality. Our objective was to update the American Cancer Society (ACS) 2013 lung cancer screening (LCS) guideline for adults at high risk for lung cancer. The guideline is intended to provide guidance for screening to health care providers and their patients who are at high risk for lung cancer due to a history of smoking. The ACS Guideline Development Group (GDG) utilized a systematic review of the LCS literature commissioned for the US Preventive Services Task Force 2021 LCS recommendation update; a second systematic review of lung cancer risk associated with years since quitting smoking (YSQ); literature published since 2021; two Cancer Intervention and Surveillance Modeling Network‐validated lung cancer models to assess the benefits and harms of screening; an epidemiologic and modeling analysis examining the effect of YSQ and aging on lung cancer risk; and an updated analysis of benefit‐to‐radiation‐risk ratios from LCS and follow‐up examinations. The GDG also examined disease burden data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms. The GDG judged that the overall evidence was moderate and sufficient to support a strong recommendation for screening individuals who meet the eligibility criteria. LCS in men and women aged 50–80 years is associated with a reduction in lung cancer deaths across a range of study designs, and inferential evidence supports LCS for men and women older than 80 years who are in good health. The ACS recommends annual LCS with low‐dose computed tomography for asymptomatic individuals aged 50–80 years who currently smoke or formerly smoked and have a ≥20 pack‐year smoking history (strong recommendation, moderate quality of evidence). Before the decision is made to initiate LCS, individuals should engage in a shared decision‐making discussion with a qualified health professional. For individuals who formerly smoked, the number of YSQ is not an eligibility criterion to begin or to stop screening. Individuals who currently smoke should receive counseling to quit and be connected to cessation resources. Individuals with comorbid conditions that substantially limit life expectancy should not be screened. These recommendations should be considered by health care providers and adults at high risk for lung cancer in discussions about LCS. If fully implemented, these recommendations have a high likelihood of significantly reducing death and suffering from lung cancer in the United States.

show abstract

“…5 However, there is still a possibility that we fail to capture key variables, particularly because lung cancer risk model variables tend to overestimate risk with an expected-observed ratio range of 0.83 to 3.69 and possess lower areas under the curve, ranging from 0.62 to 0.75. 7 Second, given a recent study showing the association between having a primary health care professional and an increased likelihood of lung cancer screening, 8 health care accessibility can be a pivotal determinant in clinical contexts while it is ensured in RCTs by design. Third, variability in adherence to lung cancer screening between the RCTs (>90% and >95% in NELSON and the NLST, respectively) and general populations (pooled adherence of 57% among 21 studies 9 ) also merits attention.…”

Section: + Related Articlementioning

confidence: 99%

Transportability Analysis—A Tool for Extending Trial Results to a Representative Target Population

Inoue,

Hsu

2024

JAMA Netw Open

View full text Add to dashboard Cite

Disparities in Receipt of Smoking Cessation Assistance Within the US

Abstract: This cross-sectional study analyzes sociodemographic variations in receiving smoking cessation assistance from health professionals by individuals who reported smoking, or quitting, within the past year.

Cited by 11 publications

References 5 publications

Prevalence of Lung Cancer Screening in the US, 2022

Prevalence of Lung Cancer Screening in the US, 2022

Screening for lung cancer: 2023 guideline update from the American Cancer Society

Transportability Analysis—A Tool for Extending Trial Results to a Representative Target Population

Contact Info

Product

Resources

About